drugset / Trial / NCT04663997
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Phase 2
Active not recruiting
200 enrolled
Canadian Cancer Trials Group
Novartis Pharmaceuticals · collabProstate Cancer Canada · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study is to find out whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard chemotherapy treatment
Timeline
- Start
- 2021-08-11
- Primary completion
- 2025-08-25
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-PSMA-617 | Other / unclassified | 7400 mbq | Other |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |